Metformin therapy to reduce weight gain and visceral adiposity in children and adolescents with neurogenic or myogenic motor deficit

Pediatric Diabetes

Volumn 11, Issue 1, 2010, Pages 61-69

  Casteels, Kristina ^a   Fieuws, Steffen ^b   van Helvoirt, Maria ^a   Verpoorten, Carla ^a   Goemans, Nathalie ^a   Coudyzer, Walter ^a   Loeckx, Dirk ^c   de Zegher, Francis ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b KU LEUVEN   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Body composition; Insulin resistance; Metformin; Neural tube defect; Neuromuscular disease

Indexed keywords

DEFLAZACORT; METFORMIN; PLACEBO;

ABDOMINAL DISCOMFORT; ABDOMINAL OBESITY; ADOLESCENT; ARTICLE; BODY FAT DISTRIBUTION; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG WITHDRAWAL; DUCHENNE MUSCULAR DYSTROPHY; EVENING DOSAGE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; MOTOR DYSFUNCTION; NAUSEA; NEUROMUSCULAR DISEASE; OBESITY; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SHORT STATURE; SPINA BIFIDA; TREATMENT DURATION; WEIGHT REDUCTION;

ADOLESCENT; BLOOD GLUCOSE; BODY MASS INDEX; CHILD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; MALE; METFORMIN; MUSCULAR DYSTROPHY, DUCHENNE; OBESITY; SPINAL DYSRAPHISM; WEIGHT GAIN;

EID: 77954434212     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2009.00512.x     Document Type: Article

References (41)

1. Liusuwan RA, Widman LM, Abresch RT, Styne DM, McDonald CM. Body composition and resting energy expenditure in patients aged 11 to 21 yr with spinal cord dysfunction compared to controls: comparisons and relationships among the groups. J Spinal Cord Med 2007, 30:S105-S111.
2. van den Berg-Emons HJ, Bussmann JB, Meyerink HJ, Roebroeck ME, Stam HJ. Body fat, fitness and level of everyday physical activity in adolescents and young adults with meningomyelocele. J Rehabil Med 2003, 35:271-275.
3. Widman LM, Abresch RT, Styne DM, McDonald CM. Aerobic fitness and upper extremity strength in patients aged 11 to 21 yr with spinal cord dysfunction as compared to ideal weight and overweight controls. J Spinal Cord Med 2007, 30(Suppl 1):S88-S96.
4. Mok E, Béghin L, Gachon P. Estimating body composition in children with Duchenne muscular dystrophy: comparison of bioelectrical impedance analysis and skinfold-thickness measurement. J Spinal Cord Med 2006, 30(Suppl 1):S88-S96.
5. Leroy-Willig A, Willig TN, Henry-Feugeas MC. Body composition determined with MR in patients with Duchenne muscular dystrophy, spinal muscular atrophy, and normal subjects. J Spinal Cord Med 2007, 30(Suppl 1):S88-S96.
6. McDonald CM, Carter GT, Abresch RT. Body composition and water compartment measurements in boys with Duchenne muscular dystrophy. Am J Phys Med Rehabil 2005, 84:483-491.
7. Aitkens S, Kilmer DD, Wright NC, McCrory MA. Metabolic syndrome in neuromuscular disease. Arch Phys Med Rehabil 2005, 86:1030-1036.
8. Nelson MD, Widman LM, Abresch RT. Metabolic syndrome in adolescents with spinal cord dysfunction. Arch Phys Med Rehabil 2007, 86:1030-1036.
9. Standards of medical care in diabetes. Diabetes Care 2008, 31:S12-S54. American Diabetes Association
10. Ibáñez L, López-Bermejo A, Díaz M, Marcos MV, de Zegher F. Metformin treatment for four years to reduce total and visceral fat in low birth weight girls with precocious pubarche. J Clin Endocrinol Metab 2008, 93:1841-1845.
11. Ibáñez L, Ong K, Valls C, Marcos MV, Dunger DB, de Zegher F. Metformin treatment to prevent early puberty in girls with precocious pubarche. J Clin Endocrinol Metab 2006, 91:2888-2891.
12. Ibáñez L, Valls C, Ong K, Dunger DB, de Zegher F. Metformin therapy during puberty delays menarche, prolongs pubertal growth, and augments adult height: a randomized study in low-birth-weight girls with early-normal onset of puberty. J Clin Endocrinol Metab 2006, 91:2068-2073.
13. Ibáñez L, Valls C, Marcos MV, Ong K, Dunger DB, de Zegher F. Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: effects of prepubertal initiation and postpubertal discontinuation of metformin treatment. J Clin Endocrinol Metab 2004, 89:4331-4337.
14. Ibáñez L, Ferrer A, Ong K, Amin R, Dunger D, de Zegher F. Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome. J Clin Endocrinol Metab 2004, 89:4331-4337.
15. Ibáñez L, Potau N, Ferrer A, Rodriguez-Hierro F, Marcos MV, de Zegher F. Anovulation in eumenorrheic, nonobese adolescent girls born small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism. J Clin Endocrinol Metab 2002, 7:5702-5705.
16. Ibáñez L, Lopez-Bermejo A, Suárez L, Marcos MV, Díaz M, de Zegher F. Metformin treatment for four years to reduce total and visceral fat in low birth weight girls with precocious pubarche. J Clin Endocrinol Metab 2008, 93:1841-1845.
17. Gómez R, Mokhashi MH, Rao J. Metformin adjunctive therapy with insulin improves glycemic control in patients with type 1 diabetes mellitus: a pilot study. J Pediatr Endocrinol Metab 2002, 15:1147-1151.
18. Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002, 25:89-94.
19. Schwimmer JB, Middleton MS, Deutsch R, Lavine JE. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2005, 21:871-879.
20. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006, 163:2072-2079.
21. Srinivasan S, Ambler GR, Baur LA. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab 2006, 91:2074-2080.
22. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996, 334:574-579.
23. Shaw RJ, Lamia KA, Vasquez D. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005, 310:1642-1646.
24. Reitman ML, Schadt EE. Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest 2007, 117:1226-1229.
25. Shu Y, Sheardown SA, Brown C. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007, 117:1422-1431.
26. Ibáñez L, de Zegher F. Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. J Clin Endocrinol Metab 2005, 90:39-43.
27. De Jager J, Kooy A, Lehert P. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 2005, 257:100-109.
28. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008, 294:E15-E26.
29. Silfen ME, Manibo AM, McMahon DJ, Levine LS, Murphy AR, Oberfield SE. Comparison of simple measures of insulin sensitivity in young girls with premature adrenarche: the fasting glucose to insulin ratio may be a simple and useful measure. J Clin Endocrinol Metab 2001, 86:2863-2868.
30. Vicini P, Caumo A, Cobelli C. The hot IVGTT two-compartment minimal model: indexes of glucose effectiveness and insulin sensitivity. Am J Physiol. 1997, 273:E1024-E1032.
31. Tahrani AA, Varughese GI, Scarpello JH, Hanna FW. Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? BMJ 2007, 335:508-512.
32. Ferland M, Després JP, Tremblay A. Assessment of adipose tissue distribution by computed axial tomography in obese women: association with body density and anthropometric measurements. Br J Nutr 1989, 61:139-148.
33. Seidell JC, Oosterlee A, Thijssen MA. Assessment of intra-abdominal and subcutaneous abdominal fat: relation between anthropometry and computed tomography. Am J Clin Nutr 1987, 45:7-13.
34. Bray GA, Jablonski KA, Fujimoto WY. Relation of central adiposity and body mass index to the development of diabetes in the Diabetes Prevention Program. Am J Clin Nutr 2008, 87:1212-1218.
35. von Eyben FE, Mouritsen E, Holm J. Intra-abdominal obesity and metabolic risk factors: a study of young adults. Int J Obes Relat Metab Disord 2003, 27:941-949.
36. McCarthy HD, Cole TJ, Fry T, Jebb SA, Prentice AM. Body fat reference curves for children. Int J Obesity 2006, 30:598-602.
37. Taksali SE, Caprio S, Dziura J. High visceral and low abdominal subcutaneous fat stores in the obese adolescent: a determinant of an adverse metabolic phenotype. Diabetes 2008, 57:367-371.
38. Després JP. Is visceral obesity the cause of the metabolic syndrome? Ann Med 2006, 38:52-63.
39. Christ-Crain M, Kola B, Lolli F. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB J 2008, 22:1672-1683.
40. Hardie DG. AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obes (Lond) 2008, 32(Suppl 4):S7-12.
41. Bacha F, Saad R, Gungor N, Arslanian S. Adiponectin in youth. Relationship to visceral adiposity, insulin sensitivity, and beta-cell function. Diabetes Care 2004, 27:547-552.